Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Northwest Biotherapeutics and Upstream Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Northwest Biotherapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 333.09%. Given Upstream Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than Northwest Biotherapeutics.
Risk & Volatility
Insider and Institutional Ownership
0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 2.4% of Northwest Biotherapeutics shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Northwest Biotherapeutics and Upstream Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Northwest Biotherapeutics | $1.38 million | 209.54 | -$60.16 million | ($18.23) | -0.01 |
| Upstream Bio | $2.85 million | 131.64 | -$143.44 million | ($2.90) | -2.36 |
Northwest Biotherapeutics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Northwest Biotherapeutics and Upstream Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Northwest Biotherapeutics | -1,736.35% | N/A | -56.34% |
| Upstream Bio | -4,955.67% | -48.40% | -46.57% |
Summary
Upstream Bio beats Northwest Biotherapeutics on 8 of the 14 factors compared between the two stocks.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
About Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
